Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.

Twist Bioscience, a US-based DNA synthesis technology developer backed by corporates Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux, went public on Wednesday in a $70m initial public offering.

The company issued 5 million shares on the Nasdaq Global Select Market priced at $14.00 each, the foot of the IPO’s $14 to $16 range, valuing it at $381m. Its shares briefly reached $14.90 but closed at $13.91 yesterday.

Twist has created a DNA synthesis platform that enables users to produce…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn